术中胸腔内热化疗治疗恶性胸膜间皮瘤
Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma.
作者信息
Okabe Kazunori
机构信息
Division of Thoracic Surgery, National Hospital Organization, Yamaguchi Ube Medical Center, Ube, Higashikiwa, Japan.
出版信息
Ann Transl Med. 2017 Jun;5(11):233. doi: 10.21037/atm.2017.03.78.
Malignant pleural mesothelioma (MPM) is a dreadful disease with a poor prognosis. Multimodality therapy including surgical macroscopic complete resection is performed to treat operable MPM. Intraoperative intracavitary hyperthermic chemotherapy for MPM was reviewed. Appropriate papers published between 2006 and present were extracted by the PubMed advanced search by MPM (Title/Abstract), chemotherapy (Title/Abstract), and hyperthermia (All fields). Among the selected papers, those written in English, and treated more than ten MPM patients were reviewed. The intraoperative intracavitary hyperthermic chemotherapy has been performed following extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) for MPM. Cisplatin was mainly used for perfusion, and the morbidity and mortality was acceptable. In conclusion, the intraoperative intracavitary hyperthermic chemotherapy following EPP or P/D for MPM might enhance local control in the chest cavity.
恶性胸膜间皮瘤（MPM）是一种预后较差的可怕疾病。对于可手术的MPM，采用包括手术肉眼完全切除在内的多模式治疗。对MPM术中腔内热化疗进行了综述。通过PubMed高级搜索，以MPM（标题/摘要）、化疗（标题/摘要）和热疗（所有字段）检索了2006年至目前发表的相关论文。在所选论文中，对英文撰写且治疗超过10例MPM患者的论文进行了综述。MPM的术中腔内热化疗是在胸膜外全肺切除术（EPP）或胸膜切除术/剥脱术（P/D）后进行的。顺铂主要用于灌注，其发病率和死亡率是可以接受的。总之，EPP或P/D术后对MPM进行术中腔内热化疗可能会增强胸腔内的局部控制。
Zotero 插件